Project Grant K08CA279766

Award Date 7/1/24
Completion Date 2/28/25
Dollars Obligated $943K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
The National Center for Advancing Translational Sciences (NCATS), a program under the Department of Health and Human Services, has awarded a $173,500 Project Grant (CFDA 93.350) to Health Research, Inc. to conduct research on the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancer. The funding will support a 2-year study that aims to investigate a novel mechanistic pathway of how chronic stress and its mediators can...
This $251,519 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support the development, refinement, and pilot testing of a nurse-led coping and supportive care intervention called "TRANSITIONS" to address the psychosocial needs of patients with triple-negative breast cancer (TNBC) as they transition from curative therapy to surveillance. The Principal Investigator, Dr. Kathryn Post, will lead this 5-year project at...
This $107,948 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by the University of Pittsburgh to investigate the role of the MALT1 protein in promoting immunosuppression in triple-negative breast cancer (TNBC). The primary objectives are to: 1) Analyze how MALT1 protease activity within TNBC cells regulates the tumor immune microenvironment through the secretion of immunosuppressive cytokines, and 2) Evaluate a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) totaling $619,764 aims to develop new combination immunotherapy strategies to enhance the anti-tumor efficacy against triple-negative breast cancer (TNBC). The award will fund research to: Increase tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor delivery system (P-aPDL1) by triggering local thrombus formation at the TNBC site using a truncated tissue...
This U01 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $665,155 in funding to The Johns Hopkins University from September 2024 through August 2029 to conduct research on defining the brain-body feedback loops that mediate stress-induced metastasis in cancer. The key objectives are to: 1) Investigate how glucocorticoids released during stress trigger neutrophil extracellular trap (NET) formation to promote metastasis; 2) Determine...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program will provide $147,656 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to study the role of stress granules in cancer initiation. The overarching goal is to determine how stress granules, which are cytoplasmic aggregates formed upon cell stress, can enhance the viability and oncogenicity of melanoma precursor cells, thereby accelerating tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $2,104,477 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The research involves profiling cancer genetic and immune phenotypic changes in samples collected from patients before, during,...
This $1,291,898.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University aims to determine the molecular mechanisms by which the protein SAMHD1 directs radiation and immunologic dynamics underlying response to immune checkpoint inhibition (ICI) therapy in breast cancer. The key research objectives are to: Elucidate how SAMHD1 governs radiation and immunologic responses that impact the efficacy of ICI in breast cancer, particularly...
This $118,912 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). The primary awardee, the University of North Carolina at Chapel Hill, will conduct experiments to determine how MHC-I loss affects tumor progression and immune cell infiltration, as well as evaluate combination...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The University of Kentucky Research Foundation to identify and target the enzyme nicotinamide N-methyltransferase (NNMT) as a novel approach to treat triple-negative breast cancer (TNBC). The $631,492 award will support a 5-year research project to: 1) define how NNMT promotes TNBC survival and metastasis by enabling cancer cells to withstand oxidative stress, 2) evaluate the...

STRESS-INDUCED IMMUNOSUPPRESSION VIA DOWNREGULATION OF INTERFERON IN TRIPLE NEGATIVE BREAST CANCER - PROJECT SUMMARY TRIPLE NEGATIVE BREAST CANCER (TNBC) IS THE MOST AGGRESSIVE FORM OF BREAST CANCER (BC) WHICH OCCURS MORE FREQUENTLY IN YOUNGER WOMEN, OFTEN DIAGNOSED ONCE THE DISEASE HAS ALREADY METASTASIZED. IT IS THE ONLY BC SUBTYPE WHERE IMMUNE CHECKPOINT INHIBITORS (ICIS) ARE APPROVED FOR USE, BUT ONLY A MINORITY OF PATIENTS RESPOND TO CURRENT ICI TREATMENTS. ONE MECHANISM OF RESISTANCE IS LOW EXPRESSION OF INTRATUMORAL CHEMOKINES CXCL9 AND CXCL10, ESSENTIAL FOR ATTRACTING ANTI-TUMOR CD8+ T CELLS INTO THE TUMOR MICROENVIRONMENT (TME). PSYCHOSOCIAL STRESS, EXPERIENCED BY MANY BC PATIENTS CAN ENHANCE IMMUNOSUPPRESSION. B-ADRENERGIC RECEPTOR BLOCKADE HAS SHOWN HIGHER SURVIVAL BENEFIT IN TNBC PATIENTS COMPARED WITH OTHER BC SUBTYPES (OBSERVATIONAL STUDIES), SUGGESTING A POSSIBILITY OF SYMPATHETIC OVERDRIVE IN TNBC. HOWEVER, THE MECHANISTIC ROLE OF PSYCHOSOCIAL STRESS IN TREATMENT RESISTANCE TO ICIS AMONG TNBC PATIENTS REMAINS UNKNOWN. WE HAVE SHOWN THAT CHRONIC STRESS AND ITS MEDIATORS, EPINEPHRINE (EPI) AND NOREPINEPHRINE (NE), DRIVE IMMUNOSUPPRESSION IN THE TME BY DECREASING CD8+ T CELLS AND INCREASING MYELOID DERIVED SUPPRESSOR CELLS AND REGULATORY T CELLS. OUR SUBSEQUENT STUDY SHOWED THAT PROPRANOLOL, A PAN-B-BLOCKER, IMPROVES RESPONSE TO ICIS IN METASTATIC MELANOMA PATIENTS. WE ALSO FOUND THAT EPI CAN MEDIATE THE INDUCTION OF PROSTAGLANDIN E2 (PGE2) IN BC TISSUES. WE AND OTHERS HAVE SHOWN THAT PGE2 INHIBITS INTERFERON (IFN)-INDUCED CXCL9/10 SECRETION. THUS, I HYPOTHESIZE THAT CHRONIC STRESS PROMOTES IMMUNOSUPPRESSION IN TNBC BY INCREASING PGE2 AND INHIBITING IFN PATHWAYS, RESULTING IN DECREASED CXCL9/10. I PROPOSE TO TEST THIS HYPOTHESIS IN THE FOLLOWING AIMS: 1) EXAMINE NE-INDUCED CHANGES IN TNBC TISSUES AND TEST THERAPEUTIC MEASURES EX VIVO; 2) STUDY IMMUNE CHANGES IN PRE- VS. POST-TREATMENT TUMOR TISSUES AND BLOOD OF METASTATIC TNBC PATIENTS RECEIVING PROPRANOLOL AND ICI; AND 3) CORRELATE VALIDATED MEASURES OF PSYCHOSOCIAL STRESS WITH THE EXPRESSION OF IFNS AND CXCL9/10 IN BC TISSUES. TO ACHIEVE THESE GOALS, I WILL UTILIZE TNBC TISSUES FROM PATIENTS IN EX VIVO STUDIES, CONDUCT A PROSPECTIVE CLINICAL TRIAL, AND EXAMINE RELATIONSHIPS BETWEEN SELF-REPORTED STRESS AND CORRELATES OF TUMOR IMMUNITY IN BANKED SAMPLES. TO GAIN MECHANISTIC UNDERSTANDING, COMPLEMENTARY STATE-OF-THE-ART MULTIPLEX TISSUE IMAGING TECHNIQUES INCLUDING CONFOCAL MICROSCOPY, IMAGING MASS CYTOMETRY, AND SPATIAL TRANSCRIPTOMICS WILL BE UTILIZED. COMPLETION OF THE PROPOSED WORK WILL PROVIDE KEY NOVEL INSIGHTS INTO THE MECHANISTIC ROLE OF THE PGE2-IFN-CHEMOKINES PATHWAY IN STRESS-INDUCED TME IMMUNOSUPPRESSION AND HELP INFORM NEW APPROACHES THAT WILL BE TRANSLATED INTO ENHANCED THERAPEUTIC BENEFIT FOR TNBC PATIENTS. THIS PROJECT WILL ADVANCE MY DEVELOPMENT INTO AN INDEPENDENT CLINICAL SCIENTIST AND TRANSLATIONAL RESEARCHER ADVANCING PRECISION IMMUNO-ONCOLOGY TREATMENTS FOR TNBC. THIS WILL BE ACCOMPLISHED IN A RICH ACADEMIC ENVIRONMENT AT ROSWELL PARK COMPREHENSIVE CANCER CENTER AND UNIVERSITY AT BUFFALO UNDER THE GUIDANCE OF AN OUTSTANDING MENTORSHIP TEAM WITH COMPLEMENTARY EXPERTISE IN THE AREAS OF BREAST CANCER, IMMUNO-ONCOLOGY, TME-ASSOCIATED CHEMOKINES, PROSTAGLANDINS, IFNS, AND PSYCHOSOCIAL STRESS.

Posted 5/31/24, 12:00 AM